Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.54 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 4/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426024 | 0.82 | ALDH1A1 (0.50) | SLC40A1ALDH1A1NFE2L2 | |
| SCHEMBL16002844 | 0.79 | PTGES2 (0.56) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL426729 | 0.76 | PTGES2 (0.54) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL28593075 | 0.75 | PTGES2 (0.52) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL16000125 | 0.75 | PTGES2 (0.52) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL426958 | 0.74 | KAT6A (0.47) | KAT6AMEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL11161302 | 0.74 | PTGES2 (0.50) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL532898 | 0.74 | PTGES2 (0.50) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL30731549 | 0.74 | PTGES2 (0.50) | PTGES2SLC40A1CCR2ACLYCCR4 | |
| SCHEMBL20714714 | 0.72 | CCR2 (0.59) | PTGES2SLC40A1CCR2ACLYCCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | PTGES2 3472/4885SLC40A1 3133/4885CCR2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.